Stock IMVT IMMUNOVANT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Immunovant, Inc.

Equities

IMVT

US45258J1025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
28.42 USD -1.83% Intraday chart for Immunovant, Inc. -6.20% -32.54%
May. 24 Immunovant Insider Sold Shares Worth $479,233, According to a Recent SEC Filing MT
Apr. 20 Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immunovant Awarded U.S. Patent for IMVT-1402
AQ
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
AQ
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
AQ
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
AQ
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
AQ
Immunovant to Present at Upcoming Investor Conferences
AQ
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
AQ
Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares
AQ
Immunovant Announces Pricing of $450 Million Common Stock Financing
AQ
Immunovant Announces Proposed Offering of $300 Million of Common Stock
AQ
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
AQ
Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
AQ
Purcell & Lefkowitz LLP Is Investigating Immunovant, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
AQ
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023
AQ
HanAll Biopharma Reports First Quarter 2023 Results and Provides Business Update
AQ
IMMUNOVANT, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
IMMUNOVANT, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMVT Stock
  4. News Immunovant, Inc.
  5. Press Releases